"Treatment"

If you want to confirm the diagnosis of nasopharyngeal cancer, you need to go to a hospital for examination. You can go to the ENT department of a regular hospital near you, or you can go to the oncology department for examination.

Prostate cancer, which has been increasing in incidence worldwide in recent years, is now a more common cancer among Japanese men. Often, patients with prostate cancer have a poor prognosis and poor survival once they have developed multiple recurrent metastases after treatment with hormones and are difficult to treat with conventional radiotherapy.

There is an urgent clinical need for new antimicrobial drugs to break through the dilemma of cIAI treatment in children and address the growing challenge of drug resistance.

Pancreatic cancer is a very complex and common tumour of the pancreas, and the malignancy of this disease is relatively high.

Approval for new FIC depression drug on the horizon!

Preoperative oxaliplatin-fluoropyrimidine chemotherapy given to colon cancer patients did not increase the risk of perioperative complications in colon cancer patients and did reduce postoperative recurrence rates, according to the results of the international phase 3/4 FOxTROT trial.

If you are suffering from itchy hair and hair loss, it is important to understand the causes of itchy hair and hair loss so that you can get to the root of the problem. For example, some people only have mild hair loss, which can be relieved after certain adjustments, while others have both itchy symptoms and hair loss symptoms that are more pronounced, so it is also important to pay attention to the right treatment

The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.

In recommendations released on 2 February 2023, the National Comprehensive Cancer Network (NCCN) recommends that doctors consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of their estrogen receptor status.

Prior to the granting of marketing authorisation by the MHRA, Biyze® had been approved by the European Commission for a number of indications and is currently the only drug approved for the treatment of MZL in Great Britain.